Post-earnings recap
Reported
Fri, Nov 18, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
The earnings report indicates that Twist Bioscience is facing challenges, as reflected in their negative EPS. The stock's decline of 2.32% suggests that investors are reacting to the cautious tone from management and the lack of revenue figures. Without guidance, uncertainty remains about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.91 | N/A | +29.07% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution about current market conditions. They are focused on adapting strategies to navigate these challenges.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—